Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: billkirn who wrote (4734)	7/5/1998 9:38:00 PM
From: Bhag Karamchandani	Read Replies (1) \| Respond to of 6136

I wish to re-inforce what you and Richard have been saying . As a long time well wisher Of AGPH I am disappointed that their research ( and the tens and tens of millions of dollars of investor equity spent on research), given their approach, have not led to the block buster drugs we were expecting from AGPH. The research has simply not lived up to its promise. Quite the contrary. As Steve Fancy has pointed out, given the past (more recent figures awaited ) history and pattern of insider sales, failure of Thymatiq, I wish AGPH would honestly tell us the real prospects for AG3340. No more spins. Attempting to move from a single drug company to a single disease company ( where rightly or wrongly there is so much talk and hype about vaccines and non PI based therapies) may be the wrong strategy as far as shareholder value goes. I wish their collaboration was in treating other diseases. Everyone recognizes the gravity of AIDS but it is arguably not the only disease that needs to be responded to with the concerted effort as AIDS (fortunately) appears to be. AGPH is busy placing expensive bets on other's efforts. If this is because of limited( 1-3 year) promise of its internal science, it may be an example of poorly managed expensive internal research- which is being addressed by AGPH by funding outside research- which may or may not prove promising - and is inevitably expensive. At what point does the internal research become irrelevant to AGPH????? At what point does AGPh start to produce results that transcend serendipity.